Quisinostat Not Any More A Magic fascination

73 m2, whereas no participant had baseline eGFR MDRD4 Quisinostat Furthermore, no differences in any variable were found between diabetics and non-diabetics. SCr did not significantly change at any time point in the non-CIN group, whereas subjects in the CIN group showed a statistically significant increase in SCr from baseline at 48 h post-procedure: 132.6 �� 22.1 ��mol/L (1.50 �� 0.25 mg/dL) versus 97.24 �� 15.91 ��mol/L (1.10 �� 0.18 mg/dL), P = 0.002. Between the two groups, a statistically significant difference in SCr selleck compound was noted only at 48 h post-procedure (Table?1 and Figure?1). No significant differences were observed in SAlb and serum Na at any time point both within and between the two groups (data not shown). Table?1. Patient demographics and study results in CIN and non-CIN groups Fig.?1. Serum creatinine (means �� SD) in CIN and non-CIN groups at various time points after contrast administration. *P ankyrin curve was 0.59 (95% CI: 0.45�C0.74), P = 0.002 for pairwise comparison between NGAL 6 h and SCr 6 h ROC curves. By multiple regression analysis, plasma NGAL at 6 h (R2 = 0.24, P